Brian Zagol, MD
Interventional Cardiology · Danville, VANPI 1902901556
Payments from drug & device makers
Across 163 payments — averaging $21.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$474
- Novartis$426
- Medtronic$413
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$366
- AstraZeneca$236
- Amgen$214
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,40799%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $474 |
| Novartis | 28 | $426 |
| Medtronic(2 entities) | 10 | $413 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 21 | $366 |
| AstraZeneca | 12 | $236 |
| Amgen | 14 | $214 |
| Novo Nordisk | 8 | $155 |
| Johnson & Johnson | 7 | $137 |
| E.r. Squibb & Sons, L.L.C. | 7 | $105 |
| Pfizer | 7 | $99 |
| Irhythm Technologies, Inc. | 3 | $92 |
| Boehringer Ingelheim | 4 | $65 |
| Merck | 3 | $50 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $46 |
| Abbott | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $39 |
| Bayer | 2 | $38 |
| Shockwave Medical, Inc | 1 | $37 |
| Penumbra, Inc. | 1 | $37 |
| Actelion Pharmaceuticals US, Inc. | 1 | $35 |
| Baxter Healthcare | 2 | $34 |
| W. L. Gore & Associates, Inc. | 1 | $34 |
| Scpharmaceuticals Inc. | 2 | $32 |
| Cvrx, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Philips North America LLC | 1 | $27 |
| Inari Medical, Inc. | 1 | $26 |
| Getinge USA Sales, LLC | 1 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $21 |
| Bardy Diagnostics, Inc. | 1 | $20 |
| Bard Peripheral Vascular, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$118
How this compares
$3,435 in reported general payments places this provider in the 35th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 364 | $340,587 |
| XareltoRivaroxaban | 411 | $312,304 |
| EntrestoSacubitril/Valsartan | 149 | $154,788 |
| FarxigaDapagliflozin Propanediol | 83 | $73,621 |
| JardianceEmpagliflozin | 54 | $40,335 |
| Repatha SureclickEvolocumab | 25 | $23,188 |
| BrilintaTicagrelor | 32 | $22,576 |
| VascepaIcosapent Ethyl | 21 | $9,531 |
| MultaqDronedarone Hcl | 12 | $9,278 |
| LivaloPitavastatin Calcium | 16 | $7,724 |
| Prasugrel Hcl | 62 | $7,212 |
| Metoprolol Succinate | 409 | $4,700 |
| Rosuvastatin Calcium | 290 | $3,365 |
| Losartan Potassium | 307 | $2,675 |
| Atorvastatin Calcium | 302 | $2,163 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $99 | $340,587364 claims |
| Johnson & JohnsonXarelto | $137 | $312,304411 claims |
| NovartisEntresto | $426 | $154,788149 claims |
| AstraZenecaFarxiga, Brilinta | $236 | $96,197115 claims |
| Boehringer IngelheimJardiance | $65 | $40,33554 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Danville
- Deepak TalrejaVirginia Beach$2M
- Rajiv TayalFredericksburg$2M
- Michael RagostaCharlottesville$1M
- Jason FoerstRoanoke$956K
- Noah JonesFalls Church$907K
- John SaxonCharlottesville$900K
- Wayne BatchelorFalls Church$723K
- Matthew SummersNorfolk$614K
- Matthew SherwoodFalls Church$512K
- Gansevoort DunningtonRichmond$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.